Document Detail


Combined analysis of HLA class I, HLA-E and HLA-G predicts prognosis in colon cancer patients.
MedLine Citation:
PMID:  24196788     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Background:Evasion of immune surveillance and suppression of the immune system are important hallmarks of tumour development in colon cancer. The goal of this study was to establish a tumour profile based on biomarkers that reflect a tumour's immune susceptibility status and to determine their relation to patient outcome.Methods:The study population consisted of 285 stage I-IV colon cancer patients of which a tissue micro array (TMA) was available. Sections were immunohistochemically stained for the presence of Foxp3+ cells and tumour expression of HLA Class I (HLA-A, -B, -C) and non-classical HLA-E and HLA-G. All markers were combined for further analyses, resulting in three tumour immune phenotypes: strong immune system tumour recognition, intermediate immune system tumour recognition and poor immune system tumour recognition.Results:Loss of HLA class I expression was significantly related to a better OS (P-value 0.005) and DFS (P-value 0.008). Patients with tumours who showed neither HLA class I nor HLA-E or -G expression (phenotype a) had a significant better OS and DFS (P-value <0.001 and 0.001, respectively) compared with phenotype b (OS HR: 4.7, 95% CI: 1.2-19.0, P=0.001) or c (OS HR: 8.2, 95% CI: 2.0-34.2, P=0.0001). Further, the tumour immune phenotype was an independent predictor for OS and DFS (P-value 0.009 and 0.013, respectively).Conclusion:Tumours showing absence of HLA class I, HLA-E and HLA-G expressions were related to a better OS and DFS. By combining the expression status of several immune-related biomarkers, three tumour immune phenotypes were created that related to patient outcome. These immune phenotypes represented significant, independent, clinical prognostic profiles in colon cancer.British Journal of Cancer advance online publication 5 November 2013; doi:10.1038/bjc.2013.696 www.bjcancer.com.
Authors:
E C M Zeestraten; M S Reimers; S Saadatmand; J-W T Dekker; G J Liefers; P J van den Elsen; C J H van de Velde; P J K Kuppen
Related Documents :
15527428 - Malassezia yeasts in the pathogenesis of atopic dermatitis.
8875958 - 8-hydroxy-2'-deoxyguanosine is increased in epidermal cells of hairless mice after chro...
2319038 - Electron microscopic observations of dyskeratosis, apoptosis, colloid bodies and fibril...
20346028 - Type 1 interferon signature in the scalp lesions of alopecia areata.
6333028 - Synergism of antiviral activity in cell cultures treated with low concentrations of int...
21712098 - Chiral lipidomics of e-series resolvins: aspirin and the biosynthesis of novel mediators.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-11-05
Journal Detail:
Title:  British journal of cancer     Volume:  -     ISSN:  1532-1827     ISO Abbreviation:  Br. J. Cancer     Publication Date:  2013 Nov 
Date Detail:
Created Date:  2013-11-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0370635     Medline TA:  Br J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophagea...
Next Document:  Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations.